- JP-listed companies
- Income statement
(130A) Income statement
Market cap
¥3.1B
P/E ratio
-5.4x
Veritas In Silico develops small-molecule drugs targeting messenger RNA using its ibVIS platform, partnering with major pharmaceutical companies like Takeda and Shionogi.
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 17 | 18 | 13 | 59 | 179 | 360 | 195 | 91 |
| Revenue growth (%) | - | |||||||
| Operating margin (%) | - | - | - | |||||
| Operating expenses | - | - | - | 166 | 169 | 186 | 235 | 272 |
| Operating income | - | - | - | -236 | -139 | 38 | -213 | -397 |
| Income before tax | -177 | -275 | -297 | -240 | -138 | 36 | -234 | -391 |
| Pretax margin (%) | -1,062.4 | -1,514.5 | -2,229 | -404.7 | -77.4 | 10 | -120 | -428.6 |
| Provision for income taxes | - | - | - | 3 | 3 | 3 | 3 | 4 |
| Effective tax rate (%) | - | - | - | |||||
| Net income | -178 | -278 | -298 | -232 | -141 | 33 | -236 | -426 |
| Earnings per share | -162 | -252.92 | -270.82 | -51.92 | -25.7 | 6.01 | -37.11 | -65.62 |
| Dividend per share | - | - | - | - | - | - | - | - |